liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Genetic Risks for Hypertrophic Cardiomyopathy and Sudden Cardiac Death
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine. Linköping University, Faculty of Medicine and Health Sciences.ORCID iD: 0000-0002-8988-5591
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background:

Hypertrophic cardiomyopathy (HCM) is a genetically and clinically heterogeneous cardiac disease associated with an increased risk of sudden cardiac death (SCD). Despite advances in genetic testing, many patients lack identified pathogenic variants, complicating risk assessment and management. This thesis explores the genetic and phenotypic landscape of HCM in southeastern Sweden through several studies aimed at expanding understanding of its causes and clinical variability.

Methods:

Five original studies integrated clinical, imaging, and genetic data from more than 300 HCM patients across a range of ages and disease presentations. Genetic testing methods included cardiomyopathy-specific gene panels, trio exome sequencing, and AI-assisted re-analysis of variants. Clinical data were retrospectively reviewed to compare genotype-positive (G+) and genotype-negative (G–) groups.

Results:

Paper I presented a rare case of a patient homozygous for a MYBPC3 missense variant, who progressed to end-stage heart failure and underwent heart transplantation. Heterozygous carriers in the family remained unaffected, suggesting a dose-dependent pathogenic effect.

Paper II demonstrated that in paediatric and early-onset HCM cases previously deemed "gene-negative," updated gene panels and trio exome sequencing uncovered pathogenic or likely pathogenic variants in 50% of cases and variants of uncertain significance in an additional 30%, underscoring the importance of revisiting negative results with expanded methods.

Paper III reported monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin (DSP) variant, suggesting a potential overlap between myocarditis and arrhythmogenic cardiomyopathy. This highlighted the diagnostic relevance of genetic testing in cases of recurrent myocarditis with familial patterns.

Paper IV described a cohort of 225 adult HCM patients in southeastern Sweden. Of those tested, 38% were genotype positive, mainly for MYBPC3 and MYH7. G+ patients were younger, had more severe hypertrophy, higher rates of family history of HCM/SCD, and greater disease burden in first-degree relatives, supporting the utility of genetic testing in clinical risk stratification.

Paper V focused on 58 apical HCM (ApHCM) patients, a less genetically understood subtype. Only 14% carried pathogenic variants, suggesting a complex genetic basis. Despite this, patients had significant clinical issues, including atrial fibrillation (41.4%), ventricular arrhythmias (29.3%), and apical aneurysms (17.2%).

Conclusions:

This thesis reinforces the complex genetic architecture of HCM and the need for tailored genetic approaches. Homozygous or biallelic variants can cause severe phenotypes, and re-analysis of inconclusive cases with updated and expanded genetic methods improves diagnostic yield, especially in paediatric HCM. The discovery of desmosomal gene variants in myocarditis suggests overlap with arrhythmogenic cardiomyopathy and supports genetic testing in atypical cases. In adult HCM, genotype-positive status is associated with earlier onset, more severe disease, and familial clustering, though genotype-negative patients remain at risk. ApHCM appears genetically distinct, less often linked to known sarcomeric variants but with significant clinical complications. As the largest genetic HCM study in Sweden, this work provides valuable population-specific insights to enhance diagnosis, family screening, and risk stratification in inherited cardiomyopathies.

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2025. , p. 170
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1983
Keywords [en]
Hypertrophic cardiomyopathy, Genetic variants, Cascade screening, Apical hypertrophy, Genetic testing, Homozygous variant, Sudden cardiac death
National Category
Medical Genetics and Genomics
Identifiers
URN: urn:nbn:se:liu:diva-218712DOI: 10.3384/9789181181319ISBN: 9789181181302 (print)ISBN: 9789181181319 (electronic)OAI: oai:DiVA.org:liu-218712DiVA, id: diva2:2006104
Public defence
2025-11-14, Aulan, Länssjukhuset Ryhov, Jönköping, 09:00
Opponent
Supervisors
Available from: 2025-10-13 Created: 2025-10-13 Last updated: 2025-10-13Bibliographically approved
List of papers
1. Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy
Open this publication in new window or tab >>Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy
Show others...
2018 (English)In: ESC Heart Failure, E-ISSN 2055-5822, Vol. 5, no 4, p. 716-723Article in journal (Refereed) Published
Abstract [en]

Hypertrophic cardiomyopathy (HCM) is a primary autosomal-dominant disorder of the myocardium with variable expressivity and penetrance. Occasionally, homozygous sarcomere genetic variants emerge while genotyping HCM patients. In these cases, a more severe HCM phenotype is generally seen. Here, we report a case of HCM that was diagnosed clinically at 39years of age. Initial symptoms were shortness of breath during exertion. Successively, he developed a wide array of severe clinical manifestations, which progressed to an ominous end-stage heart failure that resulted in heart transplantation. Genotype analysis revealed a missense MYBPC3 variant NM_000256.3:c.2618Camp;gt;A,p.(Pro873His) that presented in the homozygous form. Conflicting interpretations of pathogenicity have been reported for the Pro873His MYBPC3 variant described here. Our patient, presenting with two copies of the variant and devoid of a normal allele, progressed to end-stage heart failure, which supports the notion of a deleterious effect of this variant in the homozygous form.

Place, publisher, year, edition, pages
WILEY PERIODICALS, INC, 2018
Keywords
HCM; MYBPC3; Homozygous; Heart failure
National Category
Medical Genetics and Genomics
Identifiers
urn:nbn:se:liu:diva-150214 (URN)10.1002/ehf2.12288 (DOI)000440649400022 ()29663722 (PubMedID)
Note

Funding Agencies|Region Ostergotland (ALF) [LIO-609681]; FORSS (Medical Research Council of Southeast Sweden) [FORSS/572421]

Available from: 2018-08-22 Created: 2018-08-22 Last updated: 2025-10-13
2. Hereditary Hypertrophic Cardiomyopathy in Children and Young Adults-The Value of Reevaluating and Expanding Gene Panel Analyses
Open this publication in new window or tab >>Hereditary Hypertrophic Cardiomyopathy in Children and Young Adults-The Value of Reevaluating and Expanding Gene Panel Analyses
Show others...
2020 (English)In: Genes, E-ISSN 2073-4425, Vol. 11, no 12, article id 1472Article in journal (Refereed) Published
Abstract [en]

Introduction: Sudden cardiac death (SCD) and early onset cardiomyopathy (CM) in the young will always lead to suspicion of an underlying genetic disorder. Incited by the rapid advances in genetic testing for disease we have revisited families, which previously tested "gene-negative" for familial predominantly pediatric CM, in hopes of finding a causative gene variant. Methods: 10 different families with non-syndromic pediatric CM or hypertrophic cardiomyopathy (HCM) with severe disease progression and/or heredity for HCM/CM related SCD with "gene-negative" results were included. The index patient underwent genetic testing with a recently updated gene panel for CM and SCD. In case of failure to detect a pathogenic variant in a relevant gene, the index patient and both parents underwent clinical (i.e., partial) exome sequencing (trio-exome) in order to catch pathogenic variants linked to the disease in genes that were not included in the CM panel. Results: The mean age at clinical presentation of the 10 index cases was 12.5 years (boys 13.4 years, n = 8; girls 9 years, n = 2) and the family history burden was 33 HCM/CM cases including 9 HCM-related SCD and one heart transplantation. In 5 (50%) families we identified a genetic variant classified as pathogenic or likely pathogenic, in accordance with the American College of Medical Genetics and Genomics (ACMG) criteria, in MYH7 (n = 2), RBM20, ALPK3, and PGM1, respectively, and genetic variants of unknown significance (VUS) segregating with the disease in an additional 3 (30%) families, in MYBPC3, ABCC9, and FLNC, respectively. Conclusion: Our results show the importance of renewed thorough clinical assessment and the necessity to challenge previous genetic test results with more comprehensive updated gene panels or exome sequencing if the initial test failed to identify a causative gene for early onset CM or SCD in children. In pediatric cardiomyopathy cases when the gene panel still fails to detect a causative variant, a trio exome sequencing strategy might resolve some unexplained cases, especially if a multisystemic condition is clinically missed.

Place, publisher, year, edition, pages
MDPI, 2020
Keywords
pediatric cardiomyopathy; hypertrophic; exome sequencing; gene panel; sudden cardiac death
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-172626 (URN)10.3390/genes11121472 (DOI)000602162600001 ()33302605 (PubMedID)
Note

Funding Agencies|Region Ostergotland (ALF); Strategic Research Area in Forensic Science (Strategiomradet i Forensiska Vetenskaper); Futurum (the research council of Region Jonkoping); Swedish Society of Medicine Samariten Foundation; FORSS (Medical Research Council of Southeast Sweden)

Available from: 2021-01-24 Created: 2021-01-24 Last updated: 2025-10-13
3. Monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin gene variant
Open this publication in new window or tab >>Monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin gene variant
Show others...
2020 (English)In: ESC Heart Failure, E-ISSN 2055-5822, Vol. 7, no 3, p. 1210-1216Article in journal (Refereed) Published
Abstract [en]

Myocarditis most often affects otherwise healthy athletes and is one of the leading causes of sudden death in children and young adults. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined heart muscle disorder with increased risk for paroxysmal ventricular arrhythmias and sudden cardiac death. The clinical picture of myocarditis and ARVC may overlap during the early stages of cardiomyopathy, which may lead to misdiagnosis. In the literature, we found several cases that presented with episodes of myocarditis and ended up with a diagnosis of arrhythmogenic cardiomyopathy, mostly of the left predominant type. The aim of this case presentation is to shed light upon a possible link between myocarditis, a desmoplakin (DSP) gene variant, and ARVC by describing a case of male monozygotic twins who presented with symptoms and signs of myocarditis at 17 and 18 years of age, respectively. One of them also had a recurrent episode of myocarditis. The twins and their family were extensively examined including electrocardiograms (ECG), biochemistry, multimodal cardiac imaging, myocardial biopsy, genetic analysis, repeated cardiac magnetic resonance (CMR) and echocardiography over time. Both twins presented with chest pain, ECG with slight ST-T elevation, and increased troponin T levels. CMR demonstrated an affected left ventricle with comprehensive inflammatory, subepicardial changes consistent with myocarditis. The right ventricle did not appear to have any abnormalities. Genotype analysis revealed a nonsense heterozygous variant in the desmoplakin (DSP) gene [NM_004415.2:c.2521_2522del (p.Gln841Aspfs*9)] that is considered likely pathogenic and presumably ARVC related. There was no previous family history of heart disease. There might be a common pathophysiology of ARVC, associated with desmosomal dysfunction, and myocarditis. In our case, both twins have an affected left ventricle without any right ventricular involvement, and they are carriers of a novel DSP variant that is likely associated with ARVC. The extensive inflammation of the LV that was apparent in the CMR may or may not be the primary event of ARVC. Nevertheless, our data suggest that irrespective of a possible link here to ARVC, genetic testing for arrhythmogenic cardiomyopathy might be advisable for patients with recurrent myocarditis associated with a family history of myocarditis.

Place, publisher, year, edition, pages
WILEY PERIODICALS, INC, 2020
Keywords
Myocarditis; Arrhytmogenic cardiomyopathy; Desmoplakin gene
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:liu:diva-166470 (URN)10.1002/ehf2.12658 (DOI)000536512400053 ()32301586 (PubMedID)
Note

Funding Agencies|Region ostergotland (ALF); FORSS (Medical Research Council of Southeast Sweden); Futurum (the research council of Region Jonkoping)

Available from: 2020-06-20 Created: 2020-06-20 Last updated: 2025-10-13
4. Unravelling the Genotype of the Apical Variant of Hypertrophic Cardiomyopathy in a Swedish Cohort
Open this publication in new window or tab >>Unravelling the Genotype of the Apical Variant of Hypertrophic Cardiomyopathy in a Swedish Cohort
Show others...
2025 (English)In: Genes, E-ISSN 2073-4425, Vol. 16, no 5, article id 494Article in journal (Refereed) Published
Abstract [en]

Background: Apical hypertrophic cardiomyopathy (ApHCM) is a distinct variant of hypertrophic cardiomyopathy (HCM). Few studies have focused on the genetic determinants of this subtype. We aimed to investigate the genetic basis of apical hypertrophy in a Swedish cohort. Methods-Results: Longitudinal data on 58 unrelated index patients with ApHCM from the Southeast healthcare region in Sweden from 2010 to 2024 were assessed retrospectively. Additionally, the original raw data from genetic testing were re-evaluated using AI-based Emedgene software. Patients were 47 +/- 14 years old, and 60% males. A total of 72.4% had the pure apical type and the remaining had the mixed phenotype, dominant distal. In the cohort, 50/58 (86.2%) underwent genetic testing, of whom 7/50 (14%) were considered genotype positive for a pathogenic/likely pathogenic variant, mainly in MYH7 (43%) and in the non-sarcomeric ALPK3 gene (28.6%). A re-evaluation of the original data from genetic testing identified a previously unreported variant in the skeletal muscle alpha-actin (ACTA1) gene. Overall, 21 of 58 patients (36.2%) had HCM-related events during their disease course: 10% had a stroke, and 12% had heart failure. Atrial fibrillation was present in 41.4% and non-sustained ventricular tachycardia occurred in 29.3% of the patients. Apical aneurysm was observed in 17.2% of cases. Patients with a positive genotype were more likely to have a positive family history of HCM compared to those with a negative genotype (p = 0.020). Conclusions: In ApHCM, a positive genotype was found less frequently compared to classic HCM. Only 14% of patients with ApHCM were found to be genotype positive, indicating that apical hypertrophy represents a genetically unique population with low risk of mortality. Nevertheless, patients with ApHCM faced higher rates of atrial fibrillation, ventricular arrhythmias, and apical aneurysms.

Place, publisher, year, edition, pages
MDPI, 2025
Keywords
apical hypertrophy; genetic variant; cardiomyopathy; sarcomere; apical aneurysm
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-214230 (URN)10.3390/genes16050494 (DOI)001495653900001 ()40428316 (PubMedID)2-s2.0-105006758958 (Scopus ID)
Note

Funding Agencies|Region Ostergoetland (ALF); FORSS (Medical Research Council of Southeast Sweden); Futurum (the research council of Region Jonkoeping) [FUTURUM-941559]

Available from: 2025-06-03 Created: 2025-06-03 Last updated: 2026-07-22

Open Access in DiVA

fulltext(9080 kB)231 downloads
File information
File name FULLTEXT01.pdfFile size 9080 kBChecksum SHA-512
6ed0623be212f302aba5b7e24ee089a69f2e69bba6ff5233eaddba0ecd2d18d9dba256b192faab7211962bcc4019779379e08dfd516ce29f16ce0ab892624919
Type fulltextMimetype application/pdf
Order online >>

Other links

Publisher's full text

Search in DiVA

By author/editor
Kissopoulou, Antheia
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health Sciences
Medical Genetics and Genomics

Search outside of DiVA

GoogleGoogle Scholar
Total: 236 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
isbn
urn-nbn

Altmetric score

doi
isbn
urn-nbn
Total: 3756 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf